Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1651-1660 of 1,873) with videos related to

Pageof 188
Sort By:
The Journal of Infectious Diseases|August 12, 2025
Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trialCaroline Espersen, Niklas Dyrby Johansen, Daniel Modin, et al.
American Heart Journal|June 20, 2025
Electronically delivered, cardiovascular-focused messaging to improve influenza vaccination: Rationale, design, and baseline characteristics of the Kaiser Permanente VACCination Improvement with Nudge-based CardiovAscular Targeted Engagement (KP-VACCINATE) MegatrialAnkeet S Bhatt, Alan S Go, Rishi V Parikh, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Nature Medicine|September 1, 2024
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomesMuthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, et al.
JACC. Heart Failure|March 6, 2025
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVERRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
European Journal of Heart Failure|October 5, 2020
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Circulation|November 30, 2019
Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney ImpairmentNavkaranbir S Bajaj, Amitoj Singh, Wunan Zhou, et al.
NEJM Evidence|August 30, 2025
Cardiovascular-Focused Messaging to Improve Influenza Vaccination RatesAnkeet S Bhatt, Natalia C Berry, Rishi V Parikh, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 188

Showing results (1651-1660 of 1,873) with videos related to

Sort By:
Pageof 188
The Journal of Infectious Diseases|August 12, 2025
Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trialCaroline Espersen, Niklas Dyrby Johansen, Daniel Modin, et al.
American Heart Journal|June 20, 2025
Electronically delivered, cardiovascular-focused messaging to improve influenza vaccination: Rationale, design, and baseline characteristics of the Kaiser Permanente VACCination Improvement with Nudge-based CardiovAscular Targeted Engagement (KP-VACCINATE) MegatrialAnkeet S Bhatt, Alan S Go, Rishi V Parikh, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
Nature Medicine|September 1, 2024
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomesMuthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, et al.
JACC. Heart Failure|March 6, 2025
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVERRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
European Journal of Heart Failure|October 5, 2020
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Circulation|November 30, 2019
Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney ImpairmentNavkaranbir S Bajaj, Amitoj Singh, Wunan Zhou, et al.
NEJM Evidence|August 30, 2025
Cardiovascular-Focused Messaging to Improve Influenza Vaccination RatesAnkeet S Bhatt, Natalia C Berry, Rishi V Parikh, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 188